12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

Diaxonhit, Allergan, Bristol-Myers deal

Diaxonhit said it was notified by Bristol-Myers that the pharma decided not to continue development of AGN-209323 ( EHT/AGN 0001) and returned rights to the program to...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >